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Progesterone receptor (PR) expression and regulation of neural progenitor cell (NPC) proliferation
was investigated using NPC derived from adult rat brain. RT-PCR revealed that PRA mRNA was not
detected in rat NPCs, whereas membrane-associated PRs, PR membrane components (PGRMCs) 1
and 2, mRNA were expressed. Progesterone-induced increase in 5-bromo-2-deoxyuridine incor-
poration was confirmed by fluorescent-activated cell sorting analysis, which indicated that pro-
gesterone promoted rat NPC exit of G0/G1 phase at 5 h, followed by an increase in S-phase at 6 h
and M-phase at 8 h, respectively. Microarray analysis of cell-cycle genes, real-time PCR, and Western
blot validation revealed that progesterone increased expression of genes that promote mitosis and
decreased expression of genes that repress cell proliferation. Progesterone-induced proliferation
was not dependent on conversion to metabolites and was antagonized by the ERK1/2 inhibitor
UO126. Progesterone-induced proliferation was isomer and steroid specific. PGRMC1 small inter-
fering RNA treatment, together with computational structural analysis of progesterone and its
isomers, indicated that the proliferative effect of progesterone is mediated by PGRMC1/2. Pro-
gesterone mediated NPC proliferation and concomitant regulation of mitotic cell cycle genes via
a PGRMC/ERK pathway mechanism is a potential novel therapeutic target for promoting neuro-
genesis in the mammalian brain. (Endocrinology 150: 3186–3196, 2009)
Emerging data indicate that progesterone (P4) has multiplenonreproductive functions in the central nervous system
(CNS) to regulate cognition, mood, inflammation, mitochon-
drial function, neurogenesis, regeneration, myelination, and re-
covery from traumatic brain injury (1–6). As a neurosteroid, P4
can be generated de novo in the CNS (7–9). Developmentally, P4
is synthesized in the CNS throughout the embryonic period in
the pluripotential progenitor cells (10, 11) and reaches its
highest concentration in late gestation (12). P4-regulated neu-
ral responses are mediated by an array of progesterone recep-
tors (PRs), including the classic nuclear receptor (cPR) PR
and PRB, the seven-transmembrane domain-, and the mem-
brane-associated 25-kDa protein (25-Dx) PR membrane compo-
nents (PGRMCs) 1 and 2 (1).
P4 can promote cell proliferation in the breast (13–16) and has
both inhibitory and stimulatory effects in the uterus, depending
on cell type, the regimen of treatment, whether PRA or PRB is
expressed, the dose of 17-estradiol (E2) and P4, and when in the
cycle P4 is administered (1). As in the uterus, P4 regulation of
mitosis in the nervous system is complex. Results from multiple
laboratories have indicated that P4 regulates neural cell prolif-
eration in both the peripheral and CNS (17–20). Tanapat et al.
(21) have shown that ovariectomized rats treated with a high
dose of E2 showed enhanced hippocampal cell proliferation and
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subsequent exposure to P4 antagonized E2-induced enhance-
ment of cell proliferation after an initial increase. Interestingly,
previous work from our laboratory demonstrated that 24 h ex-
posure of embryonic d 18 rat hippocampal neurons to P4 alone
induced a 20% increase in [3H]thymidine uptake, a phenomenon
similar to that was observed after allopregnanolone (AP) ex-
posure (1), indicating that P4 alone may promote hippocampal
progenitor cell proliferation and thereby act as a neurogenic
agent.
Whereas P4 is well characterized for its neuroprotective ef-
fects in the CNS (3, 5, 22–27) and proliferative effects in the
breast and uterus (1), knowledge regarding its proliferative ca-
pability in the adult CNS, particularly in the neural stem/pro-
genitor cell population, is limited. Thus, the first series of studies
were designed to determine the neurogenic potential of P4 in
neural progenitor cells (NPCs) derived from adult rat dentate
gyrus using cellular, morphological, biochemical, and genomic
approaches. Furthermore, to determine the mechanism under-
lying P4’s actions, a second series of studies were carried out to
investigate signaling pathway and the effect of PGRMC1 small
interfering RNA (siRNA) treatment on P4’s effect.
Materials and Methods
Steroids
All steroidsused in this studywerepurchased fromSteraloids (Newport,






nanolone sulfate), 5-pregn-an-3,20-diol(allopregnanediol), and
5-pregnan-3,17,20-triol(allopregnanetriol).
Culture of rat NPCs
Rat NPCs derived from adult rat dentate gyrus (gift from Dr. Fred
Gage, Laboratory of Genetics, The Salk Institute, La Jolla, CA) were
provided as cryopreserved cells. They were cultured as described previously
(28, 29) in DMEM/Ham’s F-12 medium (1:1; Omega Scientific, Tarzana,
CA) with 1% penicillin/streptomycin/amphotericin B (Invitrogen, Grand
Island, NY), supplemented with N2 (1%; Invitrogen) and basic fibroblast
growth factor (bFGF; 20 ng/ml; Invitrogen) in a humidified incubator (37 C
and 5% CO2). Cells were plated at a density of 2  e
6 cells/flask, 7.5–15 
e4 cells/well of 96-well plates, or 2–4  e4 cells/cm2 for chamber slides for
analysis.
Immunocytochemical staining
To check the cell composition in the culture, rat NPCs (rNPCs) were
plated onto four-well chamber slides and processed as described before
(1) with the following primary antibodies (30, 31): monoclonal antibody
for neuronal class III-tubulin (NPC marker, 1:500; Covance Labora-
tories, Vienna, VA), monoclonal antibody for nestin (1:5000; Chemicon,
Temecula, CA), monoclonal antibody for proliferating cell nuclear an-
tigen (PCNA; 1:100; Zymed Laboratories, San Francisco, CA), and poly-
clonal antibody for PGRMC1 (32, 33), followed by incubation with
appropriate secondary antibodies conjugated with fluorescein isothio-
cyanate (1:200; Vector Laboratories, Burlingame, CA) or Texas Red
(1:50; Vector Laboratories). Slides were mounted with 4, 6-diamidino-
2-phenylindole (DAPI)-containing mounting medium (Vector Labora-
tories), observed by Axiovert 200M fluorescent microscope (Zeiss,
Oberkochen, Germany), and images were captured by SlideBook soft-
ware (Intelligent Imaging Innovations, Denver, CO).
5-Bromo-2-deoxyuridine (BrdU) incorporation
Cell proliferation was evaluated by measuring the incorporation of
BrdU in the S phase of the cell cycle. After 4–6 h starvation (medium
without supplements), rNPCs were loaded with 10 M BrdU in the pres-
ence or absence of bFGF and a different concentration of P4 or other
steroids in unsupplemented maintenance medium for 1 d. The cells were
then processed using the method as described previously (34, 35) with
kits purchased from Roche (Penzberg, Germany) and read with an Lmax
microplate luminometer (Molecular Devices, Sunnyvale, CA). After sub-
tracting the value of the blank (without BrdU loading), the results were
analyzed using a one-way ANOVA, followed by a Neuman-Keuls post
hoc test and presented as percentage increase vs. control.
Fluorescence-activated cell sorting (FACS) analysis
After 4 h of growth factor deprivation and incubation with vehicle
(1 e6 ethanol) or 100 pM P4 for indicated time, rNPCs were collected
into Falcon 12-  75-mm tubes (polystyrene). After fixation with 100%
ethanol and stained with propidium iodide for nuclear content, the cells
were subjected to FACS analysis. In each sample, 1  e5 cells were
counted by LSRII flow cytometer (BD Biosciences, San Jose, CA); the num-
bersof cellsunder eachphaseof cell cyclewereobtained, andanalyzedusing
the embedded cell cycle analysis tool of the FlowJo program (Tree Star Inc.,
Ashland OR).
Gene-array assay
To analyze cell-cycle gene regulation, a commercially available tar-
geted cDNA array of 112 cell-cycle regulatory genes and several house-
keeping genes (Oligo GEArray rat cell cycle microarray; SABiosciences,
Frederick, MD) was used to analyze cell-cycle gene regulation. After 6 h
starvation, rNPCs were treated with or without 100 pM P4 for 6 h, and
total RNA was isolated using TRIzol reagent (Invitrogen) as described by
the manufacturer. Ten micrograms of total RNA were reverse transcribed
into biotin-16-deoxy-uridine 5-triphosphate-labeled single-strand cDNA
andhybridizedwithnylonmembrane, followedby incubationwithalkaline
phosphate-conjugated streptavidin.Chemiluminescencewasvisualizedand
captured by ChemiDoc XRS system (Bio-Rad, Hercules, CA). The intensity
of the spots was extracted and data were analyzed using online GEArray
expressionanalysis suite (http://geasuite.superarray.com/).Glyceraldehyde-
3-phosphate dehydrogenase and Aldoa were used as internal controls. Bac-
terial plasmid (pUC18) was used as a negative control.
Real-time RT-PCR
Real-time RT-PCR was performed to validate the gene-array results.
Total RNA was prepared as described above. cDNA synthesis and PCR
amplification was carried out using iScript one-step RT-PCR kit with
SYBR green (Bio-Rad) and primers as described before (34, 35). RT-PCR
and melting curve analysis were performed in multiplicate in optimized
conditions as described by manufacturer. No other products were am-
plified because melting curves showed only one peak in each primer pair.
Fluorescence signals were measured over 40 PCR cycles and -actin was
used as internal control. The cycle number (CT) at which the signals
crossed a threshold set within the logarithmic phase was recorded and the
differences in cycle threshold (CT) were used to analyze the gene
expression in the P4- and vehicle-treated group: target geneP4/target
genevehicle  2
-CT, where CT  (CT, target gene  CT, actin)P4 
(CT, target gene  CT, actin)vehicle.
Western blot analyses
After 6 h starvation, rNPCs were treated with or without 100 pM P4
for 10–12 h and processed for Western blot as described before (34, 35).
The proliferative effects P4 were further validated by accessing PCNA
and Cell Division Cycle 2 (CDC2) at the protein level. After overnight
incubation with monoclonal antibody for PCNA (1:500; Zymed Labo-
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ratories) or polyclonal antibody for CDC2 (1:500; Novus Biologicals,
Littleton, CO), and PGRMC1 expression levels were determined using
polyclonal antibody for PGRMC1 (1:300; Sigma, St. Louis, MO). Mem-
branes were then incubated in horseradish peroxidase-conjugated goat
antirabbit or horse antimouse IgG, and results were visualized by the 3,
5, 5-tetramethyl benzidine peroxidase substrate kit (Vector Laborato-
ries). Relative amounts of PCNA and CDC2 were quantified by optical
density analysis using the UN-SCAN-IT gel automated digitizing system
(Silk Scientific, Inc., Orem, UT). The level was normalized with respect
to -actin, and data are presented as mean  SEM.
Computer modeling
All calculations were performed on a SGI Octane graphical work-
station equipped with the IRIX 6.5 operating system (Silicon Graphics
Inc., Mountain View, CA). An automated ligand-docking program,
GOLD3.0 (Genetic Optimization for Ligand Docking, Cambridge, UK;
Cambridge Crystallographic Data Center), was used to predict the bind-
ing modes of steroids into cPR binding site as described before (3, 34).
The three-dimensional structural coordinate data of human PR-ligand-
binding domain complexes with P4 was obtained from the Protein Data
Bank (PDB entry: 1A28). The three-dimensional structures of steroids
were constructed and energy minimized using the molecular modeling
program InsightII 2000 (Accelrys Inc., San Diego, CA). GOLD offers
several fitness functions, and GoldScore, which has been optimized for
the prediction of ligand binding positions, was used in the present study.
PR competitive binding
The PR binding affinity and selectivity of the steroids were deter-
mined by a fluorescent polarization competitive binding assay using pu-
rified baculovirus-expressed human PR and a fluorescent progesterone
ligand PL Red (Invitrogen) as described before (3, 34). Polarization val-
ues were plotted against the logarithm of the test compound concentra-
tion and IC50 value, the concentration of the test compound that dis-
places half of the PL Red from PR, was determined from the plot using
a nonlinear least-squares analysis using Origin, version 8 (OriginLab
Corp., Northampton, MA). Negative controls containing PR and PL Red
(equivalent to 0% inhibition) and positive controls containing only free
PL Red (equivalent to 100% inhibition) were included.
PGRMC1 siRNA treatment
Scrambled (catalogno.AM4611)oroneof threepredesignedPGRMC1
siRNAs (siRNA ID 253163, 253164, and 253165; Ambion, Austin, TX)
wasmixedwith siPORTNeoFXtransfectionagent (Ambion) toyielda final
concentration of 30 nm and siRNA transfection carried out according the
siPORT NeoFX protocol outlined by Ambion. PGRMC1 siRNA no.
253163 and 253165 targeted sequences in the noncoding region (nucleo-
tides 977-994 and 1329-1348, respectively). PGRMC1 siRNA no. 253164
targeted the polyA tail of PGRMC1 (nucleotides 1853-1870). After siRNA
treatment for24,48, and72h, rNPCswere collectedandprocessed forboth
immunocytochemically staining and Western blot analysis for PGRMC1
expression as described earlier. This pilot study revealed that optimal treat-
ment paradigm was PGRMC1 siRNA 253163 for 48 h. For Western blot
analysis, rNPCsweretransfectedwitheitherscrambledorPGRMC1siRNA
253163 for 48 h; starved for 4 h; treated with bFGF,
vehicle, or100pM P4 for10–12h;andprocessed for
Western blot analysis for PGRMC1, PCNA, and
CDC2 expression level.
Statistical analysis
All experiments were repeated three to four
times. When appropriate, data from each repli-
cate were pooled and analyzed by either a Stu-
dent t test if only two treatment groups were in-
volved or by one-way ANOVA followed by
Neuman-Keuls post hoc analysis if means of three
or more groups were compared. Data displayed in
graphs were reported as mean  SEM or fold
change  SEM. P  0.05 was considered to be
significant, regardless of the statistical test used.
Results
Characterization of NPCs derived from
adult rat dentate gyrus
The neural progenitor phenotype of rN-
PCs (gift of Dr. Fred Gage, Salk Institute, La
Jolla, California) was verified by labeling for
stem/progenitor cell marker, nestin (30, 34),
neural progenitor/neuronal marker, Tuj1
(31, 34), and PCNA, a proliferating cell nu-
clear antigen associated with transition
through S phase (34). Cells were counter-
stained with DAPI for nuclei. Whereas rN-
PCs were nestin and Tuj1 positive, only a
subset was in an active mitotic stage as in-
dicated by PCNA expression (Fig. 1A),


























FIG. 1. Characterization of NPCs derived from adult rat dentate gyrus. A, Light microscopy of adult
rNPCs. B, Rat NPCs stained for phenotypic markers. Upper panel, rNPCs stained for nestin (green) and
DAPI (blue) for nuclei; middle panel, rNPCs stained for Tuj1 (green) and DAPI (blue); lower panel, rNPCs
stained for PCNA (green) and DAPI (blue). C, RT-PCR detection of cPR and PGRMC1 and -2 expression in
rNPCs. Rat NPCs do not express detectable amounts of cPR RNA, whereas the expression of both PGMRC1
and -2 were shown. A sample without reverse transcriptase (no RT) was used as negative control. -Actin
was used as loading control.
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The expression profile of PRs in rNPCs
was determined by RT-PCR for cPR,
PGRMC1, and PGRMC2. RNA from rat
whole brain was used as positive control,
and a sample without reverse transcriptase
(no RT) was used as a negative control. Re-
sults of RT-PCR indicated that both
PGRMC1 and -2 were present in rNPCs,
whereas cPR was not detectable (Fig. 1B).
This finding is consistent with previous re-
ports that cPR is expressed in select cell pop-
ulations in brain (1, 36).
P4 promotes rNPC proliferation in a
dose-and
time-dependent manner
BrdU chemiluminescence cell prolifer-
ation ELISA was conducted to determine
the dose response and time course of P4-
induced rNPC proliferation. To eliminate
the contribution of growth factors in the cul-
ture medium, rNPCs were growth factor de-
prived for 4 h before exposure to P4 (at con-
centrations ranging from 1  e12 to 1 
e4 M), followed by BrdU ELISA. Our pre-
liminary analyses indicated that 4 h starva-
tion ensured sufficient cell synchronization
and avoided loss of rNPC proliferative ca-
pability. P4 induced a dose-dependent effect
on BrdU incorporation in rNPCs (Fig. 2A)
with an maximally effective concentration
(EC100) at 1  e
10 M (23.5  1.6% increase
vs. vehicle, P  0.05), an effect comparable
with that induced by bFGF (20 ng/ml,
31.3  1.8% increase vs. vehicle, P  0.01).
P4-inducd BrdU incorporation exhibited an
inverted-U-shape dose response with a de-
cline in incorporation evident at 1  e8 M,
maximal at 1  e5 M, and a significant
inhibitory effect at 1  e4 M. The optimal
P4 concentrations for inducing prolifera-
tion were 1  e11 to 1  e9 M. For sub-
sequent experiments, 1  e10 M (100 pM)
was selected as the P4 dose unless indi-
cated otherwise.
To verify P4 regulation on rNPC prolif-
eration, cell cycle entry was analyzed using
FACS analysis. After 4 h of growth factor
deprivation and exposure to either vehicle
or P4 for indicated time period (Fig. 2B,
a–c), rNPCs were collected and labeled with
propidium iodide for DNA content analysis.
To eliminate variations introduced across
time, percent of cells within different cell cy-
cle phases after P4 exposure was normalized
to vehicle control at the same time point and
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FIG. 2. P4 promotes rNPC proliferation in a dose- and time-dependent manner. A, Dose response of P4-induced
proliferation in rat NPCs. Rat NPCs were starved for 4 h before treatment of P4 (1  e
12 to 1  e4 M) for 24 h, and
cell proliferation was evaluated by BrdU chemiluminescence ELISA measuring BrdU incorporation. Ethanol was used
as vehicle control (1  e6). P4-induced cell proliferation showed a dose-dependent manner. Data were collected
from three independent assays, analyzed using one-way ANOVA, followed by Neuman-Keuls post hoc test, and
plotted as percentage increase vs. vehicle control. Data are mean  SEM and vehicle control was set to zero. *, P 
0.05 vs. control; **, P  0.01 vs. vehicle control; ***, P  0.001 vs. vehicle control. B, FACS analysis of 100 pM P4
effect on rNPC cell cycle progression. Rat NPCs were starved for 4 h before treatment of P4 (100 pM) or vehicle control
(1  e6 ethanol). Cells were harvested at time points indicated on the x-axis and processed for FACS analysis for
DNA content and cell cycle progression. Ba, 100 pM P4 effect on G1-phase population; Bb, 100 pM P4 effect on S-
phase population; Bc, 100 pM P4 effect on G2/M-phase population. To eliminate the variation introduced by time, at
each time point results from both groups were normalized to the vehicle control at the same time point, and vehicle
control was set to one. Data were collected from three independent experiments and plotted as percent of rNPCs in
each cell cycle in the P4-treated group vs. vehicle control (mean  SEM). *, P  0.05 vs. vehicle control; **, P  0.01
vs. vehicle control.
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trol for that time point (Fig. 2B, a–c, G0/G1 phase, S phase, G2/M
phase, respectively). P4 promoted rNPC exit of G0/G1 phase at
4 h (Fig. 2Ba, 70.2  10.6% of vehicle, P  0.05), induced a
significant increase in cellular entry into S phase beginning at 6 h
(218.6  36.2% of vehicle, P  0.05) and extended until 8 h with
a return to baseline at 9 h (Fig. 2Bb). Parallel
to the decrease in S phase population, a syn-
chronized increase in G2/M phase popula-
tion was observed at 8 h (124.3  15.2% of
vehicle, P  0.01), which ceased by 24 h. No
statistically significant differences were ob-
served between the control group and
P4-treated group at 24–72 h in G0/G1, S, or
G2/M phase populations.
Results of the FACS analysis confirmed
the BrdU dose-response data, indicating
that at 100 pM P4 is a potent mitotic agent in
rNPCs. The timely coordinated changes in
the G0/G1, S, and G2/M phase populations
indicated that P4 induced rNPC entrance
and completion of a full cell cycle. P4 in-
duced a 1-fold increase in the S-phase pop-
ulation and a subsequent 24.3  15.2%
increase in the M-phase population, indicat-
ing that only a portion of the S-phase pop-
ulation cells passed the S/M checkpoint and
to give rise to new cells. Moreover, the am-
plitude in the change of the M-phase popu-
lations is consistent with results from pre-
vious BrdU dose-response experiment,
where 100 pM P4 induced a 23.5  1.6%
increase in BrdU incorporation (Fig. 2A).
P4 regulates gene expression of cell-
cycle proteins
P4-induced proliferation predicted its
regulation of rNPC cell cycle gene expres-
sion. To determine P4 regulation of cell cycle
gene expression, RNA was extracted from
rNPCs after 6 h P4 exposure and processed
for analysis of genes known to control cell
proliferation. The 6-h time point was se-
lected based on previous FACS results be-
cause it was the time when rNPCs exhibited
the most robust increase in the S-phase cell
population. Gene array analyses indicated
that at the mRNA level, P4 induced a signif-
icant up-regulation of genes that promote
progression through the cell cycle and simul-
taneously decrease expression of the cell cy-
cle inhibitor genes (Fig. 3A). Robust in-
creases occurred in genes that promote cell
cycle progression, such as a 2-fold increase
in cyclin-dependent kinase (CDK)-4 (pro-
motes G1 phase progression) and CDK2
(promotes G1/S phase progression), a 3-fold
increase in cyclin A (promotes S/M phase
transition), and more than a 2-fold increase in Cdc2, cyclin G1
and -2, and cyclin B (promote G2/M phase progression). In con-
trast, expression of inhibitors of cell cycle progression, such as
CDKn2b, CDKn3, and Wee1, was significantly decreased. Sev-
eral well-defined cell proliferation markers (37), including
M phaseG2/M 
checkpoint
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FIG. 3. P4 regulates cell-cycle gene expression. For gene array analysis, rNPCs were starved for 4–6 h and
then treated with vehicle or 100 pM P4 for 6 h, followed by extraction of total RNA. For Western blot
analysis, after 4–6 h starvation, rNPCs were treated with bFGF, vehicle, or 100 pM P4 for 24 h; collected;
and processed for Western blotting. A, RNA was processed for DNA gene array analysis. Changes in gene
expressions were grouped according to function. P4 induced significant increase in genes that promote
progression through the cell cycle and inhibited genes associated with exiting the cell cycle (summarized in
supplemental Table 1). Two housekeeping genes (Aldoa and glyceraldehyde-3-phosphate dehydrogenase)
were used as internal controls. Two blanks and pUC18 from bacterial plasmid were used as negative
controls. Data were represented as percent change of mRNA expression in P4-treated rNPCs vs. control
(mean  SEM) as determined by OD. Data were from three separate experiments and analyzed using both
multivariant ANOVA statistical analysis and one-way ANOVA, followed by Neuman-Keuls post hoc test. *,
P  0.05 vs. vehicle control; **, P  0.01 vs. vehicle control. B, Validation of the gene-array results by real-
time RT-PCR. CT was used to analyze the ratio of gene expression in the P4-treated group and vehicle
control as follows: target geneP4/target genevehicle  2
-CT, where CT  (CT, target gene  CT, actin)P4 
(CT, target gene  CT, actin)vehicle. Data are depicted as percent increase of mRNA expression in P4-treated
rNPCs vs. vehicle control (mean  SEM) from three separate experiments. Controls were set to zero and -
actin was used as internal control. *, P  0.05 vs. vehicle control; **, P  0.01 vs. vehicle control. C,
Validation of the gene array results by Western blot analysis of two mitotic markers, PCNA and CDC2.
Ethanol was used as vehicle control and bFGF was used as positive control. Data are depicted as percent
increase of protein expression in P4-treated rNPCs vs. vehicle control (mean  SEM) from three separate
experiments. Representative Western blotting membranes were shown at the bottom; -actin was used as
the loading control. *, P  0.05 vs. vehicle control.
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Mcm5, Mcm7, and PCNA, showed a nearly 2-fold increase in
expression. Furthermore, the gene expression data were divided
into subgroups of genes known to promote or inhibit cell pro-
liferation, and the data from each subgroup of genes were sub-
jected to multivariate ANOVA (37). Results of this analysis in-
dicated a statistically significant effect of P4 treatment on cyclins,
CDKs, and CDK inhibitors (supplemental Table 1, published as
supplemental data on The Endocrine Soci-
ety’s Journals Online web site at http://
endo.endojournals.org).
Gene array results were further validated
by real-time PCR (Fig. 3B) and Western blot
analyses (Fig. 3C). Real-time PCR was per-
formed for five mRNAs coding for genes
that promote transitions through the cell cy-
cle, two genes that inhibit cell cycle progres-
sion, and two invariant genes. P4 increased
the mRNA expression level of cyclin A, cy-
clin B, PCNA, and Cdc2 and decreased the
mRNA expression of Cdkn2c and Cdkn3 at
magnitudes comparable with the gene array
data. Western blot analyses indicated that
P4 increased PCNA and CDC2 protein level
by 62.9  11.8 and 28.9  6.4%, respec-
tively (P  0.05 vs. vehicle), an effect com-
parable with that induced by bFGF (90.7 
17.2 and 35.3  15.7%, respectively, P 
0.05 vs. vehicle). Together, these data indi-
cated that P4 promoted the expression of
activators of cell-cycle progression, such as
cyclins, CDKs, and PCNA and simulta-
neously down-regulating the CDK inhibi-
tors. Moreover, S/M phase regulatory genes
exhibited the most robust changes and con-
firmed results from previous FACS analysis,
where 6 h was demonstrated to be the time
point when S phase populations peak.
P4-induced proliferation of rNPCs is
independent of its metabolites and
requires ERK signaling
Based on previous findings from our
group and others (34, 38, 39), P4 and its
metabolites can act as mitotic agents. To de-
termine whether P4 metabolites contributed
to or were required for P4-induced increase
in proliferation, rNPCs were simulta-
neously exposed to P4 and finasteride,
which at nanomolar range effectively blocks
the conversion of P4 to 5-dihydroprogest-
erone and AP (40) (Fig. 4A). The concen-
tration of finasteride was selected based on
our previous investigation that 1 M was the
maximally effective dose for inhibition of P4
conversion without inducing inhibition of
cell proliferation and/or cell death. Results
from BrdU ELISA indicated no statistically
significant difference between the P4 alone and P4 plus finasteride
group at 24 h (Fig. 4B), indicating that the proliferative effect of
P4 is not dependent on metabolism to its metabolites.
Our group earlier reported that P4 activates the ERK sig-
naling pathway to mediate its neuroprotective actions (27),
whereas AP increased proliferation through activation of the





























































































































































































FIG. 4. P4-induced proliferation of rNPC is independent of its metabolites and requires ERK signaling. A,
Pathway showing conversion of P4 to its metabolites and required enzymes. B, Rat NPCs were starved for
4–6 h and then treated with 100 pM P4 alone or 100 pM P4	finestaride for 24 h. Rat NPC proliferation
was evaluated by BrdU chemiluminescence ELISA measuring BrdU incorporation. Comparative analysis
showed no statistical significant difference between the P4-alone and P4	finesteride group. Data were
collected from at least three independent experiments and plotted as percentage increase of BrdU
incorporation in the P4-treated rNPCs vs. vehicle control (mean  SEM). C, Rat NPCs were starved for 4–6 h
and treated with 100 pM P4 alone or in combination of ERK inhibitor UO126 or in combination of the
inactive analog of UO126 (UO124). After 24 h rNPC proliferation was evaluated by BrdU
chemiluminescence ELISA measuring BrdU incorporation. P4-induced cell proliferation could be totally
abolished by ERK inhibitor UO126, and UO124 did not show significant effect. Data were collected from
five independent experiments and plotted as percentage increase of BrdU incorporation vs. vehicle control
(mean  SEM). **, P  0.01 vs. vehicle control; ***, P  0.001 vs. vehicle control; ††, P  0.01 P4 alone
vs. P4	UO126. D, Rat NPCs were starved for 4–6 h and treated with 100 pM P4 alone or in combination of
GABAA receptor antagonist bicuculline or in combination of L-type calcium channel blocker nifedipine.
After 24 h rNPC proliferation was evaluated by BrdU chemiluminescence ELISA measuring BrdU
incorporation. The proliferative effect of P4 was not blocked by bicuculline or nifedipine. Data were
collected from three independent experiments and plotted as percentage increase of BrdU incorporation
vs. vehicle control (mean  SEM). *, P  0.05 vs. control; **, P  0.01 vs. control.
Endocrinology, July 2009, 150(7):3186–3196 endo.endojournals.org 3191
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 04 May 2015. at 07:20 For personal use only. No other uses without permission. . All rights reserved.
channel (34). To determine the signaling pathway required for
P4-induced proliferation, BrdU ELISA was carried out in rNPCs
exposed to pharmacological agents to interrogate the ERK
and Ca2	-dependent systems. At 24 h, P4 induced a cumula-
tive increase of 26.3  1.6% (P  0.001 vs. vehicle) in rNPC
proliferation, an effect that was abolished by the ERK inhib-
itor UO126 and not significantly affected by the same dose of
the inactive analog of UO124 (P  0.17) (Fig. 4C). Applica-
tion of neither bicuculline (GABAA receptor antagonist) nor
nifedipine (L-type Ca2	 channel blocker) inhibited P4-in-
duced rNPC proliferation (Fig. 5D). Together, results of these
analyses indicate that P4-induced rNPC proliferation is de-
pendent on the ERK signaling pathway.
The proliferative effect of progesterone is independent
of cPR binding affinity
To determine the structure and activity relationship for P4-
induced rNPC proliferation, BrdU ELISA was used to compare
the proliferative effects of P4 and its structural analogs at the
same concentrations (Fig. 5A). Results indicated that at 24 h, P4,
AP, and ganaxolone were equally efficacious at their EC100
concentrations, with EC100 values being 1 e
10 M, 1 e8, and
1  e5 M, respectively. Epiallopregnanolone exhibited moder-
ate proliferative efficacy, whereas epipregnanolone, allopreg-
nanetriol, pregnanolone sulfate, 5-dihydroprogesterone, and
5-pregnan-3-ol were ineffective. Additionally, allopregnan-
diol induced a significant decrease in BrdU incorporation in a
dose-dependent manner, consistent with its effect on rNPC dif-
ferentiation (34). AP, epiallopregnanolone, and epipreg-
nanolone are three molecules that differ in the position of the
3-hydroxyl and 5-hydrogen groups. Change in one or both -po-
sitioned group(s) to the -position results in a decrease in the
proliferative efficacy (epiallopregnanolone) and eventually
resulting in ineffectiveness (epipregnanolone). Computa-
tional modeling revealed three critical structural features: the
18th ketone group position, the -positioned fifth hydrogen,
and the at the third hydroxyl group (Fig. 5B). Importantly,
these structural features matched with the binding features
required for PGRMC1 (41).
A parallel computational modeling of the binding modes of
tested molecules with cPR, together with a fluorescent polariza-
tion competitive cPR binding assay, indicated that there is no
clear association between the binding affinity to cPR and pro-
liferative capabilities of these neurosteroids (see supplemental
Table 2). Collectively, these data indicated no clear link between
cPR activation and rNPC proliferation.
PRGMC1 is necessary and sufficient for P4-induced rNPC
proliferation
Evidence so far has excluded the potential role of cPR in
mediating P4-induced cell proliferation, leaving PGRMC1 as a
possible candidate. To determine the correlation between
PGRMC1 and rNPC proliferation, double labeling of PGRMC1
and PCNA was conducted in rNPCs 10–12 h after P4 treatment.
Immunocytochemical analysis revealed a subpopulation of
PGRMC1-positive rNPCs (Fig. 6A). Furthermore, only PGRMC1-
positive cells were PCNA positive after P4 exposure (Fig. 6A),
indicating that PGRMC1 was correlated with P4-induced rNPC
proliferation.
To further determine whether PGRMC1 was required for
P4-induced proliferation, siRNA was introduced to knock down
PGRMC1 expression in the rNPCs. Among all the siRNAs
tested, PGRMC1 siRNA 253163 was determined to be most
efficient, with a 68.1  3.0% (P  0.05 vs. vehicle) knockdown
rate compared with scrambled siRNA control (Fig. 6B-II).
Knockdown of PGRMC1 had no effect on the basal level pro-
liferation in rNPCs under maintenance condition when bFGF is
present (28, 29), as demonstrated by the constant PCNA and
CDC2 protein expression across treatment groups (Fig. 6B, II
and III). To assess the effect of PGRMC1 depletion, rNPCs were
treated with either scrambled or PGRMC1 siRNA. After 48 h,
rNPCs were treated with bFGF, vehicle, or P4 and the ability of
P4 to promote proliferation was determined by PCNA and
CDC2 protein expression level. In response to P4, PCNA and

















































































































FIG. 5. The proliferative effect of P4 is independent of cPR binding affinity. Rat
NPCs were starved for 4 h before treatment of P4 and its analogs (1  e
12 to
1  e4 M) for 24 h, and cell proliferation was evaluated by BrdU
chemiluminescence ELISA measuring BrdU incorporation. Ethanol was used as
vehicle control (1  e6). A, P4 and its structural analogs exhibited varied effects
on rNPC proliferation. P4, AP, and ganaxolone were equally efficacious and
epiallopregnanolone exhibited moderate proliferative effect. Epipregnanolone,
allopregnanetriol, pregnanolone sulfate, 5-dihydroprogesterone, and 5-
pregnan-3-ol were ineffective, whereas allopregnandiol induced a significant
decrease in BrdU incorporation. Data were collected from three independent
assays, analyzed using one-way ANOVA, followed by Neuman-Keuls post hoc
test, and plotted as percentage increase vs. vehicle control (mean  SEM). *, P 
0.05 vs. vehicle control; **, P  0.01 vs. vehicle control; ***, P  0.005 vs.
vehicle control. B, Structure activity relationship analysis of the proliferative ability
of the steroids and their binding affinity to cPR. Results were collected from three
independent PR-binding assays and summarized in supplemental Table 2. As
highlighted in the chemical structure of AP, three structural features were
revealed to be critical for P4 and its analog-induced proliferation in rNPCs: the
ketone group at the 18 position, the -positioned hydrogen at the 5 position,
and the hydroxyl group at the 3 position.
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respectively (P  0.05 vs. vehicle). Introduc-
tion of siRNA against PGRMC1 resulted in
a 59.7 and 84.0% decrease in P4-induced
PCNA and CDC2 expression compared
with the scrambled siRNA-treated group
(Fig. 6C II and III, P  0.05). Notably,
knockdown of PGRMC1 remarkably de-
creased basal expression level of PCNA and
CDC2 mitotic markers in rNPCs (Fig. 6C, II
and III, P  0.05), suggesting that PGRMC1
could be involved in signaling pathways reg-
ulating constitutive proliferation in rNPCs.
These results further confirmed that knock-
down of PGRMC1 specifically and signifi-
cantly decreased P4-induced rNPC prolifer-
ation. Collectively, these data demonstrated
that PGRMC1 is necessary and sufficient for
P4-induced rNPC proliferation.
Discussion
Results of the present study demonstrate for
the first time that P4 increases proliferation
of adult rNPCs in a dose-dependent manner.
P4 significantly increased the expression of
genes required for progression through the
cell cycle and inhibited expression of genes
involved in cell cycle repression. Mechanis-
tic analyses revealed that rNPC proliferation
was a direct effect of P4 and not exerted via
its metabolites. Furthermore, P4-induced
rNPC proliferation is dependent on the
ERK/MAPK signaling pathway and is me-
diated by the membrane PR, PGMRC1.
P4 increased proliferation of rNPC from
female adult rat hippocampus with maximal
proliferative efficacy within the picomolar/
nanomolar range, which was reversed at
higher micromolar range. In adult female
rat, P4 plasma levels range from 1 to 200 nM,
and the concentration of P4 in the brain is
thought to closely follow circulating plasma
levels (42, 43). The effective concentration
of P4 is comparable with that of both plasma
and brain, indicating the physiological rele-
vance of P4’s mitotic effect. Other groups
have reported that P4 regulates cell prolifer-
ation in both peripheral and central nervous
system at nanomolar/micromolar ranges
(17, 18, 20). The discrepancies between the
effective P4 concentrations across studies
may arise from varied P4 responsiveness in
different cell and tissue types. Indeed, hip-
pocampal cells are more sensitive than cer-
ebellum cells in response to P4-induced neu-





















































































































































































































































































































































































FIG. 6. PGRMC1 is critical for P4-induced rNPC proliferation. siRNA against PGRMC1 was introduced to rNPCs
to determine the correlation between PGRMC1 and cell proliferation. A, left panel, rNPCs were exposed to P4
for 10–12 h and processed for immunostaining for PGRMC1 and PCNA. PGRMC1 was expressed in selected
population of rNPCs (blue arrows showing rNPCs that were PGRMC1 negative). PCNA-positive cells can be
found only in PGRMC1-positive cells (inserted image, white arrows). Right panel, Immunostaining for PGRMC1
expression in rNPCs before (top panel) and after (bottom panel) 48 h PGRMC1 siRNA 253163 treatment. B, The
effect of scramble and three different PGRMC1 siRNAs on the expression of PGRMC1 (B, I) and mitotic markers
PCNA (B, II) and CDC2 (B, III). Representative Western blotting membranes were shown (B, IV); -actin was
used as loading control. Rat NPCs were exposed to siRNA for 48 h and processed for Western blot analysis.
Results were collected from three independent experiments and plotted as OD ratio to -actin (mean  SEM). *,
P  0.05 vs. scramble control. C, The effect of scramble and PGRMC1 siRNA 253163 on P4-induced mitotic
marker expression. After 48 h siRNA treatment, rNPCs were exposed to bFGF, vehicle control (ethanol), and P4
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concentrations within the nanomolar to micromolar range, respec-
tively (1). Alternatively, P4 may promote cell proliferation via dif-
ferent signalingpathways (1)aswellasconversionto itsmetabolites
(38), leading to the different requirements in P4 concentrations.
The mitotic efficacy of P4 was comparable to bFGF as evi-
denced by BrdU incorporation and regulation of the expression
PCNA and CDC2, two well-defined and commonly used mark-
ers for cell proliferation (44). PCNA is a marker for cells in early
G1/S phase of the cell cycle and acts as a homotrimer to increase
the processing of leading strand synthesis during DNA replica-
tion. CDC2/CDK1 is the catalytic subunit of the protein kinase
complex M-phase promoting factor and is required for the G2/M
phase transition (44). Both PCNA and CDC2 expression were
up-regulated after P4 treatment, indicating that P4 promoted
rNPC entry into and completion of the cell cycle. Importantly,
FACS analysis indicated that P4-induced DNA synthesis did not
persist beyond 24 h, indicating that P4-responsive rNPCs tra-
versed the cell cycle but did not remain in a proliferative state and
thus P4, in vitro, did not induce prolonged or uncontrolled pro-
liferation. P4 may increase proliferation by speeding up cell cycle
in the same cell population or recruiting more cells into cell cycle.
Immunocytochemical analyses argued for the latter because only
PGMRC1	rNPCs entered into Gs as a result of P4 exposure;
however, the possibility of accelerated cell cycle cannot be ruled
out at this point.
We previously demonstrated that AP increased NPC pro-
liferation at an optimal dose of 100 nM (34), whereas in the
present study, P4 exhibited an optimal concentration 1000 times
lower than that of AP. It was thus unlikely that P4 promoted
proliferation via its metabolites. This was confirmed by appli-
cation of finasteride, which showed no significant effect on P4’s
action. However, recent studies from other groups suggested an
effect of P4 metabolites (39, 45). The discrepancy may due to the
differences between embryonic NPCs and adult NPCs because
polysialic acid neural cell adhesion molecule-positive progeni-
tors were obtained from postnatal d 1 rat (45). The signaling
machinery for P4 and AP may be differently expressed in em-
bryonic vs. adult NPCs. Alternatively, differences may arise from
targeting neuronal vs. glial progenitor cells. The rNPCs are pro-
neurogenesis have an increasing proportion of neuronal-like
cells in long-term cultures (
200 d in vitro) (46), whereas the
prostate-specific antigen-neural cell adhesion molecule-positive-
positive progenitors have a default differentiation to glial lin-
eages (45), and their proliferation may be more relevant to glio-
genesis. Although P4 and AP may be present at the same time
in NPCs as evidenced by the presence of 5-reductase (47), it is
possible that they exhibit distinct binding kinetics to their targets
and exert effects at different time points.
Although cPR has been reported to respond to P4 in a non-
genomic fashion via activating second messenger signaling cas-
cades (26, 27, 48), results from RT-PCR, steroid specificity anal-
ysis, and computational modeling ruled out its involvement in
P4-induced proliferation. Specifically the potent cPR agonist, 5-
dihydroprogesterone and epipregnanolone (49), showed no ef-
fect on rNPC proliferation. In fact, multiple groups have re-
ported P4 effects in the CNS of cPR knockout mice (50), pointing
to the involvement of other receptors in response to P4.
PRGMC1 is reported to mediate the response to P4 in murine
embryonic sensory neurons (51), granulose cells (33), and neo-
natal rat Purkinje cells (52), suggested to play a role in promoting
neonatal dendritic growth, spinogenesis, and synaptogenesis.
Our study indicated that siRNA-induced depletion of PGRMC1
significantly and specifically reduced P4-increased cell prolifer-
ation. These findings together with the computational modeling
analyses indicated that PGRMC1 was the key mediator of
P4-induced rNPC proliferation. siRNA depletion of PGRMC1
was not absolute and left a residual 31.8% expression and thus
could explain the residual P4 induction of proliferation markers.
Alternatively, other P4-binding receptors such as the seven-trans-
membrane domain- (1) could account for the residual P4-in-
duced proliferation, although expression of such receptors has
not been documented in rNPCs. Knockdown of PGRMC1 sig-
nificantly decreased basal expression level of mitotic markers in
rNPCs, indicating that P4 requires PGRMC1 to induced prolif-
eration, whereas PGRMC1 may respond to factors other than P4
to regulate rNPC proliferation. Indeed, PGRMC1 has been
shown to be activated by heme and steroid/sterol ligands and
SH2- and SH3-domain proteins as well as kinases, implicating a
possible function for PGRMC1 in regulating protein interactions
and intracellular signal transduction (1, 53), which may be cru-
cial for proliferation.
The underlying mechanism for the correlation between ele-
vated expression of PGRMC1 and cell proliferation remains un-
clear. One potential explanation is the neurotrophic activity of
the secreted PGRMC1 family member neudesin, which directly
stimulates MAPK and Akt signaling to promote proliferation
and neuronal differentiation in mouse NPCs (54, 55). Our results
indicating that P4-induced, PGRMC1-dependent cell prolifera-
tion required ERK signaling pathway are consistent with these
earlier findings suggesting that P4-induced proliferation via the
ERK signaling pathway generalizes to other cell systems.
P4 is well known for its neuroprotective effects within the
CNS and has been used as a myelinating agent and as a treatment
for traumatic brain (4). In the aged brain, both the pool of neural
stem cells and their proliferative potential are markedly dimin-
ished (56–58). The discovery that P4 could promote adult rNPC
proliferation highlights the potential use of P4 as a regenerative
agent in adult brain. Indeed, several studies report that admin-
istration of P4 could improve cognitive performance in the aging
mouse when compared with control groups (59–61). Together
with our present data, these findings suggest a promising strategy
for promoting neurogenesis in the adult brain. Furthermore, the
finding that estrogen receptor and PGRMC1 were mutually ex-
clusive in breast tumor sections, and PGRMC1 labeling in-
creased in hypoxic areas of the tumor (62, 63) suggests that
FIG. 6 (cont). for 10–12 h and processed for Western blot analysis. PGRMC1
siRNA significantly and specifically reduced the expression of PGRMC1 (C, I),
blocked the increase of PCNA (C, II) and CDC2 (C, III) in response to P4, and had
no significant effect on bFGF-induced mitotic marker expression. Representative
Western blotting membranes were shown (C, IV); -actin was used as loading
control. Results were collected from three independent experiments and plotted
as percent increase vs. vehicle control (mean  SEM). *, P  0.05; **, P  0.01;
§, P  0.05 between vehicle control in the control group and PGRMC1 siRNA
253163 group; , P  0.05 vs. P4 treatment in scramble control group; †, P 
0.05 vs. bFGF treatment in PGRMC1 siRNA 253163 group.
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targeting PGMRC1 may be a novel approach to promote pro-
liferation in brain and avoid tumorogenic effects in estrogen re-
ceptor-positive cells.
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